Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BCLI

BCLI - BrainStorm Cell Therapeutics Inc Stock Price, Fair Value and News

$0.63+0.05 (+8.62%)
Market Closed

Price Targets

BCLI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCLI Price Action

Last 7 days

6.8%

Last 30 days

5%

Last 90 days

-3.1%

Trailing 12 Months

-68.3%

BCLI RSI Chart

BCLI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCLI Valuation

Market Cap

7.0M

Price/Earnings (Trailing)

-0.64

Price/Free Cashflow

-0.95

BCLI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

BCLI Fundamentals

BCLI Earnings

Earnings (TTM)

-10.8M

Earnings Growth (Yr)

22.23%

Earnings Growth (Qtr)

27.45%

BCLI Profitability

Return on Equity

140.99%

Return on Assets

-785.94%

Free Cashflow Yield

-104.76%

BCLI Investor Care

Shares Dilution (1Y)

107.82%

Diluted EPS (TTM)

-1.46

About BrainStorm Cell Therapeutics Inc

BCLI
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
 CEO
 WEBSITEbrainstorm-cell.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES44

BrainStorm Cell Therapeutics Inc Frequently Asked Questions

BCLI is the stock ticker symbol of BrainStorm Cell Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of BrainStorm Cell Therapeutics Inc is 6.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BCLI's fair value in chart for subscribers.

The fair value guage provides a quick view whether BCLI is over valued or under valued. Whether BrainStorm Cell Therapeutics Inc is cheap or expensive depends on the assumptions which impact BrainStorm Cell Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCLI.

In the past 10 years, BrainStorm Cell Therapeutics Inc has provided -0.335 (multiply by 100 for percentage) rate of return.